ABSTRACT
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive, potentially fatal condition characterized by increased pulmonary vascular resistance due to pulmonary arteriole remodelling, which ultimately leads to right heart failure. 1 As such, the survival of PAH patients is closely related to the right ventricular (RV) function, 2 where the accurate assessment of RV function is pivotal to the management of PAH patients. Right heart catheterization (RHC) is the gold standard for the evaluation of
SUMMARY AT A GLANCE
The prognostic values of cardiovascular magnetic resonance (CMR)-derived right ventricular (RV) ejection/filling parameters in idiopathic pulmonary arterial hypertension (IPAH) patients were examined. RV time to peak ejection rate (TPER) and TPER/time of a cardiac cycle (TCC) were found to reflect RV early systolic function, and thus may be prognostic predictive values for long-term cardiac impairment in IPAH patients.
cardiopulmonary haemodynamics and RV function. However, the procedure is invasive and is accompanied with a risk of ionizing radiation exposure. Echocardiography as a low-cost, non-invasive alternative is widely practiced in clinical settings, but its applications in cardiopulmonary haemodynamic measurements are limited due to a number of known shortcomings. 3, 4 During the past decade, cardiovascular magnetic resonance (CMR) has been increasingly applied to the evaluation of cardiovascular disease, and has been established as a non-invasive, accurate and reproducible method for evaluating RV function. 5, 6 CMR is suitable for quantifying regurgitant volumes, delayed enhancement, myocardial strain and coronary perfusion of right heart. 7 Several studies have demonstrated the value of CMR to predict the prognosis of pulmonary hypertension. [8] [9] [10] [11] [12] [13] These results showed that many RV volume-based indices, for example, stroke volume index (SVI), ejection fraction (EF) , end diastolic volume index (EDVI) and end systolic volume index (ESVI), could be useful predictors. [8] [9] [10] [11] [12] The CMR-derived RV ejection/filling parameters can be determined based on CMR volumetric measurements as a part of standard procedure in clinical care. These parameters include RV peak ejection rate (PER), peak filling rate (PFR), time to peak ejection rate (TPER) and time to peak filling rate (TPFR). Under normal physiological conditions, the cardiac cycle consists of systolic and diastolic phases, which can be divided into isovolumic contraction phase, ejection period, isovolumic relaxation phase and filling period. Ejection period includes rapid and reduced ejection periods. Filling period includes rapid and reduced filling periods. PER happens in rapid ejection period and PFR in rapid filling period. TPER refers to the period from the beginning of blood ejection to the moment when the ejecting blood flow reaches maximal rate. TPFR refers to the period from the beginning of filling to the moment when the filling blood flow reaches peak rate.
In an exploratory study by Bianco et al., 14 left ventricular (LV) PFR was found to reflect left heart function in healthy volunteers. However, the value of RV ejection/ filling parameters for the assessment of RV function in PAH patients remains to be established. The goal of this study was to compare the baseline cardiopulmonary haemodynamics measured by RHC with RV volume-based indices measured by CMR to evaluate the ability of baseline RV ejection/filling parameters to assess RV function, and to examine the prognostic predictive value of these criteria in PAH patients. With the consideration that different clinical types of pulmonary hypertension have diverse pathogenesis, which can affect RV function and complicate the outcomes, 1, 15 we limited the enrolment criteria to idiopathic PAH (IPAH) patients.
METHODS

Patients
Patients, who were diagnosed with IPAH for the first time between March 2010 and December 2013, were prospectively recruited. They had not received any PAH-targeted therapy before diagnosis. IPAH is a diagnosis of exclusion and was made in accordance with standard guidelines. 16 Clinical history, symptoms, signs, electrocardiograph (ECG), chest X-ray, transthoracic echocardiogram, pulmonary function test, highresolution computed tomography of the chest, ventilation/perfusion scintigraphy lung scan and pulmonary angiography (if necessary) were assessed to exclude pulmonary hypertension due to left heart disease or lung diseases or chronic thromboembolism pulmonary hypertension. The haemodynamic criteria for PAH include mean pulmonary arterial pressure (mPAP) ≥25 mm Hg and pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg measured at rest by RHC. Additional specific diagnostic tests including haematology, biochemistry, immunology, serology and ultrasonography were performed to exclude other forms of PAH. Exclusion criteria include: (i) patients with other clinical types of pulmonary hypertension; (ii) patients with unstable conditions; (iii) patients with contraindications of CMR and (iv) patients who declined to participate in the study. As CMR scanning is not a routine examination for PAH in our hospital, written informed consents were obtained from all enrolled patients before they received this procedure without charge. This study complied with the Declaration of Helsinki and was approved by the Institutional Review Board of Fuwai Hospital (the ethical approval number: 402).
Clinical evaluation
Exercise capacity was evaluated by the World Health Organization (WHO) functional class. The 6-min walk test (6MWT) was performed according to American Thoracic Society guidelines. 17 Immediately after the 6MWT, the Borg dyspnoea score was obtained.
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Right heart catheterization
Haemodynamic parameters including mean right atrial pressure (mRAP), mPAP and PCWP were recorded for RHC examination. Cardiac output (CO) was measured by the thermodilution method (the mean value of threetime measurement). Body surface area (BSA) was calculated according to the Du Bois formula, 19 that is BSA = 0.07184 × weight 0.425 × height 0.725 . Pulmonary vascular resistance index (PVRI) was calculated using the following equation: PVRI = (mPAP − PCWP) × BSA/CO.
CMR protocol
The CMR scanning was performed using a Siemens 1.5 T Avanto scanner (Siemens Medical Solutions, Erlangen, Germany) in all patients within 1 week of the diagnosis of RHC. During this period, all patients were in stable condition. Phase offset errors were corrected by simultaneous ECG recording. Breath-hold short-axis cine images encompassing the whole LV and RV from apex to base were acquired by a gradient echo pulse sequence (TrueFISP; Siemens Medical Solutions) (repetition time/echo time, 34/1.6 ms; flip angle, 60
; field of view, 280 × 340 mm Volumes of both ventricles and parameters of ventricular volume ejection/filling dynamics were calculated using the analytical software (Medis QMass). PER and PFR were calculated from the first derivative of the ventricle volume versus time curve (Fig. S2 , Supplementary Information). The negative peak component of the curve was considered as PER. Similarly, the first positive peak component of the curve was considered as PFR. The second maximum is related to the late diastolic filling due to atrial contraction. Considering the possible effect of the length of time of a cardiac cycle (TCC) on TPER and TPFR, we adjusted TPER and TPFR by TCC, which was calculated as TCC (ms) =60 s × 1000/heart rate, to show their proportions in the period of a cardiac cycle.
End point and follow-up
Each patient was followed up by telephone, outpatient or in hospital examinations in a 6-month interval. They were included in this study from the date of signing informed consent till they reached primary end point. The designed primary end point was any causes of mortality, lung transplantation or atrial septostomy. However, during the follow-up, no patient underwent lung transplantation or atrial septostomy. Clinical deterioration was also applied in this study and defined as all-cause mortality, worsening WHO functional class, a ≥15% reduction in 6-min walk distance (6MWD) or allcause hospitalization (including for transplantation, atrial septostomy or introduction of a parenteral prostacyclin analogue for any reasons). 20, 21 No patients were lost to follow-up during the period of this study.
Statistical analysis
The variables were presented as the mean AE SD or frequency with percentage (%). The correlations of variables were assessed using Pearson's correlation coefficient. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify independent variables associated with end points. Results of these analyses were expressed as hazard ratio (HR) with 95% CI. Kaplan-Meier survival analyses were performed for the cumulative occurrence of end points. Between-group comparisons were made using the log-rank test. A P-value of <0.05 was considered to indicate statistical significance. Statistical analyses were performed using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS
Baseline demographic, clinical and haemodynamic patient characteristics
Among all 41 patients enrolled, 34 patients received PAH-targeted therapy 22 including endothelium receptor antagonists, phosphodiesterase type-5 inhibitors and prostanoids combined with conventional therapy as soon as their diagnoses were confirmed. However, seven patients only received conventional supportive therapy because of financial issues. The median followup time was 824 days (range: 629.5-1238.5 days). During this period, 13 patients had clinical deterioration, including WHO functional class worsening (5 patients), re-hospitalization due to right heart failure aggravation (5 patients) and death due to right heart failure (3 patients). Another four patients died after WHO functional class worsening or re-hospitalization. The baseline demographic, clinical and haemodynamic (measured by RHC) characteristics of study patients are presented in Table 1 . The baseline haemodynamic characteristics measured by CMR are presented in Table S1 (Supplementary Information).
Correlations between CMR-derived RV ejection/filling parameters and haemodynamics
As presented in Table 2 , CMR-derived RV PER was associated significantly with CMR-derived RV SVI (r = 0.574, P < 0.001) and RV cardiac index (CI, r = 0.611, P < 0.001), but had no significant correlation with the RV EDVI (r = 0.201, P = 0.208) and PVRI (r = −0.134, P = 0.403). CMR-derived RV PFR was associated significantly with CMR-derived RV SVI (r = 0.545, P < 0.001), RV CI (r = 0.662, P < 0.001) and EDVI (r = 0.425, P = 0.006), but had no correlation with PVRI (r = 0.027, P = 0.866).
Predictive value of CMR-derived RV volume ejection/filling parameters on clinical outcome
Univariate Cox regression analysis determined that Nterminal pro-brain natriuretic peptide (NT-proBNP) and RV TPER/TCC were predictive factors for primary end point (Table S2 , Supplementary Information). Considering the predictive value of RV EDVI 8 and the possible effect of EDVI on TPER, NT-proBNP, RV TPER/ TCC and RV EDVI were examined using a multivariate Cox regression analysis. Results showed that none of these parameters had the ability to predict mortality (Table 3) . Univariate Cox regression analysis found that mRAP, RV TPER and RV TPER/TCC were predictive factors for clinical deterioration (Table S2 , Supplementary Information). When RV TPER and RV TPER/TCC were adjusted by mRAP and RV EDVI in multivariate Cox regression analyses, respectively, results showed that RV TPER and RV TPER/TCC still had the ability to predict time to clinical deterioration (RV TPER: HR = 1.010, 95% CI: 1.003-1.017, P = 0.005; RV TPER/TCC: HR = 1.085, 95% CI: 1.031-1.141, P = 0.002; Table 3 ). Bivariate Cox regression analyses showed that TPER and TPER/TCC independently predict clinical deterioration (Table 4) .
Kaplan-Meier survival analyses showed that patients with RV TPER ≥199.01 ms or RV TPER/TCC ≥20.02% had worse prognosis (log rank: P = 0.036; log rank: P = 0.007; Fig. 1 ).
DISCUSSION
Novel findings from the present study are that (i) CMRderived RV TPER and TPER/TCC were found to be promising predictors for long-term prognosis in IPAH patients; (ii) CMR-derived RV ejection/filling parameters can reflect RV systolic function.
In the study by Lee et al., 23 RV PER was significantly lower in adult patients who underwent tetralogy of Fallot repair surgery and had deteriorating RV function. Theoretically, PER happens at the rapid ejection period and is a parameter of RV early systole. In this study, RV PER was found to have significant correlation with RV SVI and CI which are reliable indicators of RV systolic function. [8] [9] [10] [11] [12] RV PER was also found to be independent of PVRI and EDVI. Its independence of RV pre-and after-loads indicates that RV PER may be an indicator of RV early systolic function.
In this study, we also found that RV TPER had the ability to predict the prognosis of IPAH. Patients with RV TPER ≥199.01 ms had worse prognosis. Considering the effect of the time of cardiac cycle, TPER/TCC was employed and IPAH patients with RV TPER/TCC ≥20.02% also had worse outcomes. It appears that the longer RV TPER lasts or the larger proportion of RV TPER accounts for the worse systolic function of RV in a cardiac cycle. In IPAH, excessive RV after-load, such as higher PVRI and tricuspid regurgitation, can induce an elevated RV wall tension during systole with prolonged myocardial contraction. 2 A prior study on the left heart found that, 24 LV TPFR, measured by radionuclide cine angiography, was significantly prolonged in patients with LV tachycardia which can result in LV diastolic dysfunction. Another study, 25 using an echocardiographic method of speckle tracking-derived strain to compare the time of RV contraction (time to peak longitudinal systolic strain, PLSS) between patients with RV dysfunction and normal subjects, found that time to PLSS was generally longer in patients with RV dysfunction. These pieces of evidence indicate that ventricular systolic or diastolic dysfunction may affect TPER or TPFR. Since TPER is independent of EDVI and PVRI, it may provide another indicator for RV early systolic function.
The CMR-derived RV EF is an established parameter for RV systolic function with prognostic predictive values. 8, 10, 26 Interestingly, in this study, neither RV PER nor RV TPER had correlations with RV EF. RV EF is affected by both RV pre-and after-loads, and reflects the integral RV systolic function, which covers isovolumic contraction phase, rapid ejection period and reduced ejection period. On the other hand, RV PER and TPER may only reflect RV early systolic function. In addition, RV EF did not confer a prognostic value for IPAH in this study, which was in agreement with the study by Swift et al., 27 while in the study by Sato et al., 28 RV EF alone provides no appreciable prognostic predictive value unless when combined with RA reservoir. This may be explained by the following reasons: we only enrolled IPAH patients who had not received PAH-targeted therapy at baseline; patients were younger and had better WHO functional class than previous studies 8, 10 ; subsequent long-term targeted therapy may enhance RV EF and improve RV function of patients who responded to targeted therapy 29 and all of the reasons stated above may compound the predictive effect of baseline RV EF.
In this study, RV TPER and RV TPER/TCC, which reflect RV early systolic function, were the only CMR parameters to predict clinical deterioration of IPAH. However, they had no correlation with other CMR parameters which were thought to reflect RV systolic function. So, we suggest that they may be independent indicators of RV systolic function in the long term compared with other CMR parameters in a newly diagnosed IPAH cohort. Further validations are warranted with a larger IPAH cohort. We are also interested in how the parameters would change after a long-term targeted therapy.
Our study had several limitations. First, the study consisted of patients referred to a single tertiary centre, which may constitute a referral bias. Second, the study population was limited and may reflect a relatively small sample of the entire IPAH population. Given that IPAH is a relatively low occurrence disease, with a prevalence rate of 5.9 cases per million adult populations, 30 it may be challenging to conduct largescale trials with newly diagnosed IPAH cohorts. Third, as specific therapy is widely used and registry data suggested that the 7-year survival rate for PAH patients from time of diagnostic right-sided heart catheterization was 49%, 15 some parameters need further investigation to test their ability to predict prognosis. Finally, we did not perform a second CMR scan in the followup, so we do not have the data about how the parameters mentioned above would have changed after receiving targeted therapy.
In conclusion, CMR-derived RV TPER and TPER/ TCC can reflect RV early systolic function, and may be promising predictors for long-term prognosis in IPAH patients.
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